A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension (Bax24)

AstraZeneca

Status and phase: Active, not recruiting; Phase 3

Conditions: Resistant Hypertension

Treatments: Drug: Baxdrostat; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06168409

D6970C00009

2023-507640-36-00 (Registry Identifier)

Details and patient eligibility

About

This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of which is a diuretic).

Full description

This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg baxdrostat versus placebo, administered once a day (QD) orally, on the reduction of ambulatory SBP in participants with rHTN, defined as BP targets not being achieved in an individual despite the use of at least 3 antihypertensive agents of different classes (at maximum tolerated dose in the judgement of the Investigator), one of which is a diuretic.

Enrollment: 217 patients

Sex: All

Ages: 18 to 130 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant must be ≥ 18 years old, at the time of signing the informed consent.
• Mean seated SBP on AOBPM of ≥ 140 mmHg and < 170 mmHg at Screening.
• Have a stable regimen of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one should be a diuretic), at maximum tolerated dose in the judgement of the Investigator, for at least 4 weeks prior to Screening (participants who do not meet this criterion may be rescreened at the Investigator's discretion). Beta blockers used to treat other conditions (ie, migraine, HF, coronary artery disease) should not be counted as an antihypertensive medication for the purpose of qualifying for this study.
• Have eGFR ≥ 45 mL/min/1.73 m2 at Screening.
• Serum potassium (K+) level ≥ 3.5 and < 5.0 mmol/L at Screening, determined as per central laboratory
• Randomization Criteria: mean ambulatory SBP of ≥ 130 mmHg at randomisation.

Exclusion criteria

• Mean seated SBP on AOBPM ≥ 170 mmHg at Screening.
• Mean seated DBP on AOBPM ≥ 110 mmHg at Screening.
• Serum sodium level < 135 mmol/L at Screening, as per central laboratory.
• Participant has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.
• New York Heart Association functional HF class IV at Screening.
• Persistent atrial fibrillation.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

217 participants in 2 patient groups, including a placebo group

2 mg baxdrostat

Experimental group

Description:

2 mg baxdrostat administered orally, once daily (QD).

Treatment:

Drug: Baxdrostat

Placebo

Placebo Comparator group

Description:

Placebo administered orally, once daily (QD)

Treatment:

Drug: Placebo